Matinas BioPharma Holdings (MTNB) Gains from Sales and Divestitures (2018)

Matinas BioPharma Holdings (MTNB) reported Gains from Sales and Divestitures of $521044.0 for Q3 2018, up 40.4% quarter-over-quarter from $371122.0 in Q2 2018.

Matinas BioPharma Holdings (MTNB) Gains from Sales and Divestitures (2018) Analysis & Trends

Matinas BioPharma Holdings (MTNB) has 1 years of Gains from Sales and Divestitures data on file, last reported at $521044.0 in Q3 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Matinas BioPharma Holdings 4.60 Mn 2.15 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2018 521,044.00
Sep 30, 2018 521,044.00
Jun 30, 2018 371,122.00
Jun 30, 2018 371,122.00